Tamoxifen-inducible loss of EZH2 results in heightened intestinal immune reactivity. A–D , demonstration of weight change ( A ), clinical disease activity index ( DAI , B ), colon length ( C ), and blinded histologic inflammatory index ( D ) in tamoxifen-treated CRE × EZH2 fl/fl animals versus tamoxifen-treated CRE EZH2 WT/WT controls exposed to 3% DSS. E , representative colon histologic section demonstrating significant inflammation and ulceration. Statistical significance for weight change was determined using the Holm-Sidak method, with α = 5.000% ( p
{}